Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...

Starting in 2026, NIBRT training will be piloted at Heartland BioWorks’ Indianapolis headquarters with hands-on training beginning in 2027.

Tumors trigger T-cell exhaustion through a TSP-1–CD47 signaling pathway. Blocking it can restore immune strength and improve cancer treatment.